Regeneron Pharmaceuticals (NASDAQ:REGN) VP Jason Pitofsky Sells 431 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN traded down $2.79 during mid-day trading on Monday, hitting $654.74. The stock had a trading volume of 824,797 shares, compared to its average volume of 1,094,190. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The company has a 50 day simple moving average of $588.03 and a 200-day simple moving average of $567.90. The stock has a market capitalization of $69.39 billion, a price-to-earnings ratio of 15.68, a P/E/G ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $834.42.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating the consensus estimate of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. Regeneron Pharmaceuticals’s revenue was up .9% compared to the same quarter last year. During the same quarter last year, the business earned $12.46 earnings per share. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

Analyst Ratings Changes

A number of brokerages have recently commented on REGN. Sanford C. Bernstein raised their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a report on Wednesday, August 27th. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Guggenheim boosted their price target on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 8th. Finally, Redburn Atlantic raised Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $796.57.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in REGN. Dodge & Cox boosted its stake in shares of Regeneron Pharmaceuticals by 64.6% during the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after acquiring an additional 1,502,198 shares in the last quarter. Norges Bank purchased a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $628,151,000. Nuveen LLC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $343,764,000. Pacer Advisors Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 2,296.9% during the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company’s stock valued at $258,366,000 after acquiring an additional 390,374 shares during the period. Finally, Acadian Asset Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 234.7% in the 2nd quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock valued at $244,480,000 after acquiring an additional 326,583 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.